Product Reports Resources Pricing Login Book a demo

Gelesis

Biotech & Life Sciences · Boston, United States · Founded 2006 · Public via SPAC 2021

Gelesis is a biotechnology company focused on developing innovative therapies for gastrointestinal (GI) related chronic diseases. The company's proprietary platform features the first and only superabsorbent hydrogel made exclusively from naturally derived building blocks. Gelesis primarily serves adults who are overweight or obese, with a Body Mass Index (BMI) of 25 to 40, by offering products like PLENITY, which aids in weight management when combined with diet and exercise. The company operates in the healthcare and biotechnology market, targeting conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Type 2 diabetes, and Chronic Idiopathic Constipation (CIC). Gelesis generates revenue through the sale of its hydrogel-based therapies and continues to expand its pipeline of potential treatments for various GI-related conditions. Keywords: biotechnology, hydrogel, gastrointestinal, obesity, weight management, chronic diseases, NAFLD, NASH, Type 2 diabetes, CIC.

Valuation $0–100M
Revenue $10–50M
Headcount <100
Total funding $100–500M

Investors

13 investors on Gelesis's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage
BIRD Foundation
Series A 3 investors entered at this stage
PureTech
QIC BioVentures
OrbiMed
Series B+ 9 investors entered at this stage
Cormorant Asset Management
Invesco
Vitruvian Partners
China Medical System Holdings
PV Capital Management
Pacific investment Management
Kennedy Lewis Investment Management
Capstar Special Purpose Acquisition Corp
Theras

Global footprint

Where Gelesis has talent and traffic

Workforce by country
4 countries with
team presence
🇮🇹 Italy87.9%
🇺🇸 United States6.1%
🇬🇧 United Kingdom3%
🇮🇱 Israel3%
4 countries shown
Web traffic by country
2.4K monthly visits
across markets
🇺🇸 United States54.2%
🇮🇹 Italy50%
Top 2 markets shown

Talent graph

The shape of Gelesis's talent

Dealroom maps Gelesis's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

15 team members profilednamed & role-tagged by Dealroom
56 employeestotal headcount
3 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Gelesis's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$47M patent portfolio · 18 active families

Estimated portfolio value
$47M
88.0% of market cap · 4.9× smaller than top peer Ascendis Pharma ($234M)
18 active patent families
Where Gelesis innovates Carboxylic acidCarboxymethyl celluloseCelluloseComposite materialGastric fluid

Where Gelesis concentrates vs peers

Each axis is a top-10 topic across Gelesis and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Gelesis

An AI-synthesized read of the highest-engagement posts about Gelesis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Gelesis on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.